Abstract

The medical, economic, and social effects of painful chronic wounds such as anal fissures, which frequently prove refractory to treatment with commercially available medications, are often underestimated by clinicians. Those types of injuries, which afflicted individuals are often reluctant to discuss with healthcare providers, can lead to a greatly restricted lifestyle; result in depression, anxiety, social isolation, and embarrassment; require extended or repeated hospital stays; and create a financial burden for the patient and for society. Because interpatient variables can preclude the effectiveness of standardized mass-produced wound-healing products, a compounded formulation that can be formulated to include drugs proven effective in safe but off-label uses and that can be modified as patients’ medical needs require may achieve the therapeutic goal. In this report, 2 such agents shown to promote wound healing are profiled: the vasodilator nifedipine, a first-generation calcium channel blocker that is used to treat hypertension and angina pectoris; and pentoxifylline, a synthetic dimethylxanthine derivative that facilitates vasodilation, improves erythrocyte flexibility, enhances blood flow, and reduces blood viscosity. Formulations that incorporate those drugs, which are underrecognized as effective healing agents when compounded as directed, are included for easy reference.

Related Keywords

• painful chronic wounds
• anal fissures
• nifedipine
• vasodilator
• wound healing
• first-generation calcium channel blocker
• pentoxifylline
• synthetic dimethylxanthine derivative
• erythrocyte flexibility
• blood flow
• blood viscosity
• formulations
• quality of life
• social isolation
• topical preparations
• pressure ulcers
• antioxidant
• inflammation
• anti-inflammatory agent
• diabetes
• diabetic ulcers

Related Categories

• DERMATOLOGY
• FORMULATIONS
• PAIN MANAGEMENT
• WOUND CARE
• ALLERGY/IMMUNOLOGY/INFLAMMATION
• DOSAGE FORMS/DRUG CARRIERS